Candriam S.C.A. Purchases Shares of 318,086 Immunome, Inc. $IMNM

Candriam S.C.A. purchased a new stake in shares of Immunome, Inc. (NASDAQ:IMNM) in the 2nd quarter, Holdings Channel reports. The fund purchased 318,086 shares of the company’s stock, valued at approximately $2,958,000.

Other institutional investors have also recently made changes to their positions in the company. Teacher Retirement System of Texas boosted its holdings in shares of Immunome by 49.0% in the 1st quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company’s stock valued at $117,000 after buying an additional 5,712 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Immunome by 56.8% in the 1st quarter. Bank of New York Mellon Corp now owns 193,147 shares of the company’s stock valued at $1,300,000 after purchasing an additional 69,944 shares during the last quarter. Arizona State Retirement System grew its holdings in Immunome by 66.2% during the first quarter. Arizona State Retirement System now owns 18,764 shares of the company’s stock worth $126,000 after purchasing an additional 7,476 shares during the period. KLP Kapitalforvaltning AS increased its position in Immunome by 140.8% during the first quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company’s stock worth $115,000 after buying an additional 10,000 shares during the last quarter. Finally, Readystate Asset Management LP bought a new stake in Immunome in the first quarter valued at approximately $1,509,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Trading Up 3.8%

NASDAQ IMNM opened at $17.14 on Friday. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -5.81 and a beta of 1.96. The company has a 50 day moving average of $13.54 and a 200-day moving average of $10.79. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $18.46.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. On average, equities research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analyst Ratings Changes

IMNM has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Wednesday, October 8th. Guggenheim reaffirmed a “buy” rating and set a $25.00 target price on shares of Immunome in a report on Monday, August 25th. Wedbush reaffirmed an “outperform” rating and issued a $21.00 target price on shares of Immunome in a research report on Friday, November 7th. Craig Hallum started coverage on Immunome in a research note on Friday, September 5th. They issued a “buy” rating and a $26.00 price target for the company. Finally, The Goldman Sachs Group initiated coverage on Immunome in a research report on Monday, September 22nd. They set a “buy” rating and a $26.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Immunome presently has an average rating of “Moderate Buy” and a consensus target price of $23.44.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.